Prevention of recurrent hepatitis B virus infection after liver transplantation: Hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis

L. H. Katz, M. Paul, D. G. Guy, R. Tur-Kaspa

Research output: Contribution to journalReview articlepeer-review

85 Scopus citations

Abstract

Objectives. To evaluate antiviral prophylaxis against hepatitis B virus (HBV) following liver transplantation. Methods. Systematic review and meta-analysis. Clinical trials and comparative cohort studies comparing the use of hepatitis B immunoglobulin (HBIg), antivirals, or both following liver transplantation for HBV infection were included. The primary outcome was reappearance of hepatitis B surface antigen (HBsAg). Other outcomes included all-cause and HBV-related mortality, HB-related active liver disease, and reappearance of HBV DNA after transplantation. Relative risks (RR) with 95% confidence intervals (CIs) are reported. Results. Twenty studies (22 comparisons) were included. Ten studies compared HBIg to combination treatment, 9 compared antivirals to combination treatment, and 3 compared lamivudine (LAM) to HBIg. Combination treatment reduced HBsAg reappearance (RR 0.28; 95% CI 0.12-0.66), and was superior to HBIg alone in all other outcome measures. Combination treatment was significantly better than antivirals in preventing reappearance of HBsAg (RR 0.31; 95% CI 0.22-0.44), even when low-dose HBIg was given. No significant difference was found between HBIg and LAM monotherapy for all measured outcomes. Major limitations with regard to comparability of the study groups in non-randomized trials were revealed. Conclusions. Combination treatment with HBIg and LAM reduced HBV recurrence following liver transplantation, compared with HBIg or LAM alone, and reduced mortality compared with HBIg alone.

Original languageEnglish
Pages (from-to)292-308
Number of pages17
JournalTransplant Infectious Disease
Volume12
Issue number4
DOIs
StatePublished - 1 Aug 2010
Externally publishedYes

Keywords

  • adefovir
  • hepatitis B
  • hepatitis B immune globulin
  • lamivudine
  • liver transplantation
  • prevention

Fingerprint

Dive into the research topics of 'Prevention of recurrent hepatitis B virus infection after liver transplantation: Hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this